Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
September 19, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies, approximately 31% of...
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 09, 2024 16:53 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 09, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
March 10, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 04, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the closing of its previously announced underwritten public offering.
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
February 29, 2024 17:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024 23:30 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the pricing of its underwritten public offering of common stock.
Arcutis Announces Proposed Public Offering
February 28, 2024 16:10 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024 05:50 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter and year ended December 31, 2023, and provided a business update.